HK1246807A1 - Mk2抑制劑肽的製劑 - Google Patents

Mk2抑制劑肽的製劑

Info

Publication number
HK1246807A1
HK1246807A1 HK18106201.2A HK18106201A HK1246807A1 HK 1246807 A1 HK1246807 A1 HK 1246807A1 HK 18106201 A HK18106201 A HK 18106201A HK 1246807 A1 HK1246807 A1 HK 1246807A1
Authority
HK
Hong Kong
Prior art keywords
formulation
inhibitor peptides
peptides
inhibitor
Prior art date
Application number
HK18106201.2A
Other languages
English (en)
Inventor
Cynthia Lander
Colleen Brophy
Caryn Peterson
Original Assignee
Moerae Matrix Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Moerae Matrix Inc filed Critical Moerae Matrix Inc
Publication of HK1246807A1 publication Critical patent/HK1246807A1/zh

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4702—Regulators; Modulating activity
    • C07K14/4703—Inhibitors; Suppressors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/32—Macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. carbomers, poly(meth)acrylates, or polyvinyl pyrrolidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/007—Pulmonary tract; Aromatherapy
    • A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
    • A61K9/0075—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy for inhalation via a dry powder inhaler [DPI], e.g. comprising micronized drug mixed with lactose carrier particles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/007—Pulmonary tract; Aromatherapy
    • A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
    • A61K9/0078—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy for inhalation via a nebulizer such as a jet nebulizer, ultrasonic nebulizer, e.g. in the form of aqueous drug solutions or dispersions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
    • A61K9/145—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
HK18106201.2A 2015-01-08 2018-05-14 Mk2抑制劑肽的製劑 HK1246807A1 (zh)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201562101190P 2015-01-08 2015-01-08
PCT/US2016/012650 WO2016112292A1 (en) 2015-01-08 2016-01-08 Formulation of mk2 inhibitor peptides

Publications (1)

Publication Number Publication Date
HK1246807A1 true HK1246807A1 (zh) 2018-09-14

Family

ID=56356475

Family Applications (1)

Application Number Title Priority Date Filing Date
HK18106201.2A HK1246807A1 (zh) 2015-01-08 2018-05-14 Mk2抑制劑肽的製劑

Country Status (14)

Country Link
US (2) US10087225B2 (zh)
EP (1) EP3242886A4 (zh)
JP (1) JP2018502860A (zh)
KR (1) KR20170102900A (zh)
CN (1) CN107406489A (zh)
AU (1) AU2016205125A1 (zh)
BR (1) BR112017014737A2 (zh)
CA (1) CA2972916A1 (zh)
HK (1) HK1246807A1 (zh)
MX (1) MX2017008994A (zh)
RU (1) RU2017128077A (zh)
SG (1) SG11201705559RA (zh)
WO (1) WO2016112292A1 (zh)
ZA (1) ZA201704495B (zh)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2874561T3 (es) 2014-09-17 2021-11-05 Celgene Car Llc Inhibidores de MK2 y usos de los mismos
EP3595658A4 (en) * 2017-03-16 2020-11-25 Celgene CAR LLC FORMS AND COMPOSITIONS OF A MK2 INHIBITOR
JP7216073B2 (ja) 2018-03-13 2023-01-31 株式会社Adeka 非水電解質二次電池
WO2021211854A1 (en) * 2020-04-16 2021-10-21 Cai Gu Huang Inhalable formulation of a solution containing tiotropium bromide
CN111647088B (zh) * 2020-06-29 2023-05-02 东北师范大学 细胞渗透短肽tat-hns-3及对炎性疾病的应用

Family Cites Families (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1521000A (en) 1975-06-13 1978-08-09 Syntex Puerto Rico Inc Inhalation device
US4227522A (en) 1978-09-05 1980-10-14 Syntex Puerto Rico, Inc. Inhalation device
US4192309A (en) 1978-09-05 1980-03-11 Syntex Puerto Rico, Inc. Inhalation device with capsule opener
US4778054A (en) 1982-10-08 1988-10-18 Glaxo Group Limited Pack for administering medicaments to patients
CA1224992A (en) 1982-10-08 1987-08-04 Robert E. Newell Device for administering medicament to patients
FI88112C (fi) 1985-07-30 1993-04-13 Glaxo Group Ltd Anordning foer administrering av laekemedel till patienter
JPH05963A (ja) 1990-04-13 1993-01-08 Toray Ind Inc ポリペプチド類組成物
US6582728B1 (en) 1992-07-08 2003-06-24 Inhale Therapeutic Systems, Inc. Spray drying of macromolecules to produce inhaleable dry powders
WO2006050247A2 (en) * 2004-10-29 2006-05-11 Neose Technologies, Inc. Remodeling and glycopegylation of fibroblast growth factor (fgf)
EP2155228B1 (en) 2007-01-10 2014-04-02 Purdue Research Foundation Polypeptide inhibitors of hsp27 kinase and uses therefor
ES2547229T3 (es) 2007-08-07 2015-10-02 Purdue Research Foundation Inhibidores de cinasa y usos de los mismos
CA2741302C (en) * 2008-10-20 2017-02-28 Moerae Matrix, Inc. Mapkap kinase inhibitor polypeptide for treating or preventing adhesions
EP2378875B1 (en) * 2008-12-10 2018-05-30 Purdue Research Foundation Cell-permeant peptide-based inhibitor of kinases
US9890195B2 (en) 2009-07-27 2018-02-13 Purdue Research Foundation MK2 inhibitor compositions and methods to enhance neurite outgrowth, neuroprotection, and nerve regeneration
EP2575855A4 (en) * 2010-05-24 2014-03-12 Moerae Matrix Inc METHOD FOR TREATING OR PREVENTING VASCULAR GRAFT BREAKAGE
US9890200B2 (en) * 2011-04-12 2018-02-13 Moerae Matrix, Inc. Compositions and methods for preventing or treating diseases, conditions, or processes characterized by aberrant fibroblast proliferation and extracellular matrix deposition
AU2012242768B2 (en) * 2011-04-12 2017-10-12 Moerae Matrix, Inc. Compositions and methods for preventing or treating diseases, conditions, or processes characterized by aberrant fibroblast proliferation and extracellular matrix deposition
US20140072613A1 (en) * 2012-09-10 2014-03-13 Cynthia Lander Compositions and Methods for Treating Cutaneous Scarring
US9102015B2 (en) * 2013-03-14 2015-08-11 Siemens Energy, Inc Method and apparatus for fabrication and repair of thermal barriers
JP2016518358A (ja) * 2013-04-11 2016-06-23 ヴァンダービルト ユニバーシティーＶａｎｄｅｒｂｉｌｔ Ｕｎｉｖｅｒｓｉｔｙ ポリプレックス

Also Published As

Publication number Publication date
US20160200782A1 (en) 2016-07-14
US10087225B2 (en) 2018-10-02
AU2016205125A1 (en) 2017-07-13
RU2017128077A (ru) 2019-02-08
RU2017128077A3 (zh) 2019-09-30
JP2018502860A (ja) 2018-02-01
BR112017014737A2 (pt) 2018-01-16
SG11201705559RA (en) 2017-08-30
ZA201704495B (en) 2019-01-30
EP3242886A4 (en) 2018-08-29
MX2017008994A (es) 2018-09-18
US20190031730A1 (en) 2019-01-31
KR20170102900A (ko) 2017-09-12
AU2016205125A2 (en) 2017-10-19
WO2016112292A1 (en) 2016-07-14
EP3242886A1 (en) 2017-11-15
CA2972916A1 (en) 2016-07-14
CN107406489A (zh) 2017-11-28

Similar Documents

Publication Publication Date Title
IL259560A (en) Inhibitors of the menin-mll interaction
ZA201705527B (en) TGF-ß INHIBITORS
IL251051A0 (en) mk2 inhibitors and their uses
GB201513010D0 (en) Novel formulation
HK1246807A1 (zh) Mk2抑制劑肽的製劑
GB201521059D0 (en) Inhibitors of metallo-beta-lactamases
IL284236A (en) Modifications and uses of conotoxin peptides
HK1251979A1 (zh) 肽組合物和使用方法
GB201501004D0 (en) Inhibitors
HK1257745A1 (zh) 肽組合物
GB2540026B (en) Fragment retentive coating formulation
GB201506316D0 (en) Novel peptide
SG11201609739UA (en) Derivatives of dolaproine-dolaisoleuine peptides
ZA201803032B (en) Pharmaceutical compositions of dimethyl fumarate
IL257803B (en) Peptide analogs derived from vdac1
GB201509891D0 (en) Formulation
HK1251593A1 (zh) Bace1抑制劑肽
GB201520949D0 (en) Inhibitors
GB201511255D0 (en) Formulation
GB201504211D0 (en) Use of peptides
PT3280430T (pt) Péptido qbp1 para uso na prevenção ou tratamento de perturbação de stress pós-traumático, transtorno de stress agudo e síndrome geral de adaptação
GB201502834D0 (en) Composition of objects
GB201506360D0 (en) Novel peptide
GB201508527D0 (en) Novel formulation
GB201504662D0 (en) Formulation